Table 1.

Summaries of index cases and cases that have been reported in the literature.

Case	Age	Gender	Symptoms	Corneal exam	Onset	Treatment	Outcome
1a	64	F	Blurred vision	Edema, endothelial fine deposits	2 d	PO acyclovir, loteprednol	No thinning, BCVA down 1 line at 1 mo
2a	75	F	Burning, blurred vision	Central edema with folds, SPK	4 d	PO valacyclovir, loteprednol/tobramycin	No thinning, BCVA down 1 line at 1 mo
3a	58	F	Haloes, blurred vision	Central edema with folds, SPK	1 d	PO acyclovir, diclofenac	BCVA stable at mild stromal haze at 2 wk
45	60	F	Haloes	Central epithelial and stromal edema	1 wk	PO valacyclovir, prednisolone, sodium chloride	BCVA stable at 4mo
55	54	F	Pain, blurred vision	Mild central stromal edema	1 wk	prednisolone	BCVA stable at 2mo
613	55	F	Pain, blurred vision	Anterior stromal haze, rare AC cell	5 d	lotedprednol	Thinning, BCVA decreased by one line, refractive shift
714	55	F	Blurred vision	Central edema, AC fibrin	1 d	“intensive topical steroid”	Thinning, BCVA stable, central corneal haze, refractive shift at 2 mo
814	59	F	Blurred vision	Anterior stromal haze	2 d	“intensive topical steroid”	Thinning, BCVA stable, central stromal scar, no refractive shift at 3 mo
915	63	F	Photophobia, blurred vision	Central corneal edema, haze	2 d	prednisolone	Thinning, BCVA decreased two lines, mild central stromal haze at 8 mo
1015	56	F	Blurred vision	Central stromal edema and haze	1 d	prednisolone, nepafenac	Thinning, BCVA decreased one line, faint central stromal haze at 6 mo
1115	46	F	Blurred vision	Diffuse dense stromal opacification	2 d	prednisolone	Thinning, BCVA decreased one line, cornea clear at 11mo
1215	56	F	Blurred vision	Central stromal haze	2 wk	defluprednate, hypertonic saline	Thinning, BCVA decreased one line, cornea clear at 7mo

Cases in order of mention.

Abbreviations: AC, anterior chamber; BCVA, best-corrected visual acuity; d, day/s; F, female; mo, month; PO, oral; wk, weeks.

^aIndex cases that are described in this report.